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Abstract 
Biosensors are increasingly heralded for their potential to create inexpensive diagnostic devices 
which are sensitive, selective and easy to use. One of the key categories of biosensor are 
immunosensors, which have historically used antibodies as bioreceptors. Though widely used, 
antibodies bring inherent limitations such as variability, limited stability and their reliance on animal 
sources.  
This has led to the development of alternative immuno-reagents such as non-antibody binding 
proteins (NABPs). These are low molecular weight proteins which largely avoid the aforementioned 
advantages of antibodies. They are commonly produced by bacteria enabling the use of DNA 
technology to manipulate bioreceptors at the molecular level.  
Single chain VHHs (commonly known as nanobodies) are an antibody derived NABP adapted from 
camelid heavy chain antibodies which are the isolated binding domain. Whilst nanobodies have been 
used for diagnostic and therapeutic applications, they have limited demonstration in biosensors. 
In this study, both antibodies and nanobodies were used to construct a biosensor.  In addition 
nanobody performance was optimised by introducing a novel peptide spacer. The role of nanobody 
orientation and spacing was thus investigated and spacer length was optimised, leading to an 
increase in the sensitivity of the biosensor.  
Highlights: 
x Nanobodies have been used on impedimetric immunosensors to detect rabbit IgG 
x Unmodified nanobody sensors displayed a decrease in resistance upon analyte recognition. 
x Nanobodies were modified with a peptide spacer, effectively reversing this phenomena. 
x The use of a spacer also increased the sensitivity of the immunosensor.  
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1. Introduction  
A biosensor may be considered a three component system comprising: (a) the sample or analyte, (b) 
a transducer mechanism or bioreceptor and (c) a signal output.  This report focuses on how altering 
the bioreceptor may be a crucial step in overcoming the barriers in the production of sensitive, low 
cost biosensors for both diagnostic and analytical applications. Though many sensors have been 
developed at the proof –of –concept level, there are only a few examples which have made the leap 
into the commercial market [1,2].  
Most of the binding sensors developed to date rely on antibodies, the primary recognition agent of 
the immune system [3] and will be referred to as immunosensors throughout. Though antibodies are 
common reagents with well understood binding physics which allow the use of routine methods, 
there are a number of major drawbacks. These include batch to batch variability when using 
polyclonal antibodies, stability of the antibodies and their large size (150kDa) which precludes the 
possibility of protein engineering. Antibodies may also bring issues of cross reactivity which cannot 
be identified until after production. These technical shortcomings are in addition to the ethical issues 
raised by their reliance on animal use and the financial issues raised with their associated cost [4,5]. 
For these reasons, there is a movement towards the use of recombinant monoclonal antibodies and 
the use of non-antibody binding proteins (NABPs), the latter of which may be easily expressed using 
bacterial techniques which allow the continuous production of a stable protein with no variation. 
Whilst this article focuses on the use of nanobodies, the lessons learned may support findings 
relevant to other types of NABP or engineered Fab fragments or single chain variable fragments 
(ScFvs). There are currently a number of candidate NABPs for biosensor development such as 
darpins [6] Adhirons [7] and affybodies [8]. Though the benefits of these receptors have been 
previously demonstrated using optical biosensor systems [9], there are limited reports on their 
application in electrochemical sensors and specifically a lack of data reported for impedimetric 
immunosensors [10]. There is no work to date focussing on both the orientation and inclusion of a 
peptide spacer to investigate the influence of bioreceptor height above the electrode on detection 
of analyte and signal generation.  
The nanobody binding protein used in this study is an IgG fold domain which has been isolated from 
cammellid heavy chain only “Immunoglobulin New Antigen Receptors” (IgNARs). cDNA from 
lymphocytes was taken from immunised Cammellidae [11–13]. The cDNA can be sourced from 
lymphocytes isolated from blood taken from the host, avoiding animal sacrifice and contributing to 
the 3R’s of animal use in research.  
The cDNA extracted was isolated using PCR and used to construct a phage display library that could 
be screened to identify binding candidates for nanobody synthesis before sequencing and 
subcloning the DNA into a stable plasmid vector [14]. Screening can also be carried out at this stage 
to check for cross reactivity with candidate biomolecules which may commonly cross react with 
receptors [15]. This enables the elimination of receptors which cross react before the receptor is 
generated en-masse.  
Once the DNA is ligated into a plasmid, it contains the sequence for a monoclonal-type binder and 
batch to batch variability is eliminated. This means that only one immunisation is necessary for a 
potentially endless source of nanobodies, producing a binder that is more reliable when compared 
to polyclonal antibody production techniques, as well providing the potential for lower cost [16]. 
These benefits have enabled the development of novel [17–20], as well as showing early promise in 
the field of diagnostics [20,21]. 
The nanobody used in this report was engineered to include a His6-Tag for easy purification.  In 
addition the plasmid was further engineered to create nanobodies with an engineered peptide 
spacer of 5, 10 or 15 amino acids (a GGGGS motif repeated respectively) with a unique cysteine at 
the N-terminus to enable oriented conjugation of the receptor using thiol chemistry,  the plasmids 
are summarised in Appendix A. Along with orientation, the use of spacers permitted the 
optimisation of receptor distance from the transducer surface, a parameter which may greatly 
impact the electrochemical signal generated.  
Whilst the majority of reports aim to attach the bioreceptor intimately at biosensor interface, this 
may cause undesired effects such as a limitation in analyte binding due to steric hindrance. By 
providing a spatially coherent peptide spacer, these problems may be overcome as well as an 
improved degree of receptor orientation. The effect of steric hindrance has been demonstrated as a 
critical parameter in biosensor signal generation in previous studies [22–25]. It is hypothesised that 
the use of nanobodies will highlight the importance of orientation of the bioreceptor. As a 
comparison to the novel nanobody biosensors, data has been collected on antibody based 
biosensors; the variety of bioreceptors used in this study is illustrated in Figure 1.  
The sensor constructed in the study was developed to specifically detect rabbit IgG, for the 
commercial demands of the antibody development industry. The sensor developed will provide an 
accessible method for assaying antibody concentration in both sera and in prepared antibody 
products. Currently, a multi-step procedure is needed to quantify rabbit IgG accurately, this is  
inefficient in terms of both time and resources as it often relies on relatively large sample volumes.  
2. Materials & Methods 
2.1. Expression and Purification of nanobodies.  
A series of pHEN6 vectors was generated to create anti-rabbit IgG nanobodies, based on ab191866 
(Abcam), the sequence was cloned into each modified pHEN6 vector using PstI and BstEII sites 
(Error! Reference source not found.) and modified vectors were generated by ligating in the 
sequence for include C-terminal spacers with a G4S motif (repeated for 5, 10 and 15 amino acid 
spacers with a terminal cysteine (Error! Reference source not found.) followed by a His6-tag. This 
was achieved using BstEII and EcoRII sites. Following ligation, plasmids were transformed into WK6 
E.Coli cultures using the heat shock method [26] and cultures were grown on Ampicillin containing 
TB –Agar plates pre-heated to 37 °C. Individual col onies were then picked and added to 5 ml LB –
ampicillin media to form starter cultures. The following day, 2 ml of this culture as added to 500 ml 
LB –ampicillin and IPTG was used to induce cultures overnight. 
Cells were collected by centrifugation at 3,000 xg for 30 min.  The periplasm was then extracted using 
TES buffer (0.2M Tris-HCL 0.5M Sucrose 0.5mM EDTA) at 4 °C, shaking on ice for 1 hr. Finally, cell deb ris 
were collected by centrifugation at 6,800 xg for 5 min. The Periplasm extract was then purified on a 
Ni2+ chelating column as previously described [27] and imidazole was removed by dialysing the 
nanobody against PBS.  
2.2. Reduction of nanobody dimers  
The purified nanobody at 1 mg.ml-1 was incubated with 50 mM 2-mercaptoethylamine (2-MEA), in 
degassed PBS plus 10 mM EDTA pH 7.4 for 90 min at 37  ? ?dŚŝƐƐĞůĞĐƚŝǀĞůǇƌĞĚƵĐĞĚƚŚĞĚŝƐƵůĨŝĚĞ
bonds, reducing Nanobody dimers into monomers.  Buffer exchange was then executed using 
Amicon® filters (3,000 MWCO) which were centrifuged at 14,000xg for 10 min to remove excess 
MEA. Buffer was replaced three times with previously degassed 1×PBS plus 10mM EDTA pH 7.4. 
Reduced nanobodies were then used immediately to prevent recombination of reduced nanobodies.  
2.3. Immunoprecipitation  
For immunoprecipitation studies, unmodified nanobodies were conjugated to N-Hydroxy 
succinimide (NHS) (GE Healthcare) and the modified nanobodies were conjugated to 
Sulfolink®(Sigma)  sepharose beads according to manufacturers’ protocols. Non-specific binding was 
reduced by blocking beads with glycine in the case of NHS beads and cysteine for Sulfolink beads 
(50mM cysteine in 50mM Tris-Hydroxymethylaminomethane plus 5Mm EDTA).  
To confirm the affinity of the nanobodies had not been compromised, the beads were incubated 
ǁŝƚŚ ? ? ?ʅůĚŝůƵƚĞĚƌĂďďŝƚƐĞƌĂ ? ? ?A?ǀ ?ǀƐĞƌĂŝŶW^ ?ĨŽƌ ?ŚƌƐ ?ĨƚĞƌďŝŶĚŝŶŐ ?ĂŵŝůĚĂĐŝĚǁĂƐŚǁĂƐ
performed using 100 mM sodium citrate (pH 4.0) and a final RIPA Buffer wash (50mM NaCl, 1% (v/v) 
IGEPAL CA-630®, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS and 50 mM Tris, pH 8.0) to 
remove non-specifically bound protein from the beads.  
For elution, a two stage procedure was employed. First, 100 mM glycine (pH 2.0) elution buffer was 
used to interrupt nanobody-antigen binding and elute bound analyte. Then, a second elution buffer 
containing PBS + 100 mM DTT was used to liberate the modified nanobody from the Sulfolink® bead. 
This provided confirmation that the nanobody had bound via the engineered cysteine residue.   
2.4.  Identification of eluates 
For identification, eluates from immunoprecipitation were subjected to non-reducing SDS-PAGE. 
^ĂŵƉůĞƐĐŽŶƚĂŝŶŝŶŐ ?ʅŐƉƌŽƚĞŝŶŝŶ ?ʅůƌƵŶŶŝŶŐďƵĨĨĞƌ ? ? ? ?ŵDdƌŝƐƉ, ? ? ? ? ? ?A? ?ǁ ?ǀ ?^^ ? ? ?A?
(v/v) glycerol, 0.01% (w/v) bromophenol blue (w/v)] were heated for 10 min at 70  ?ĂŶĚƚŚĞŶĂĚĚĞĚ
to pre-cast gels (4-12% acrylamide) (Invitrogen). Gels were run at 200 V for 50 min in 1x Trid-glycine 
running buffer.  Following separation, the gels were either stained using Instant Blue® Coomassie 
stain, according to manufacturer’s instruction or used for immunoblotting.  
In immunoblot experiments, samples were transferred to nitrocellulose membrane at 30 V for 70 
min in transfer buffer and transfer was confirmed using Ponceau-stain which was subsequently 
washed using TBST (20 mM Tris, 150 mM NaCl 0.1 % (v/v) Tween-20 pH 7.6). Membranes were then 
blocked using 5% (w/v) BSA in TBST before being probed with the appropriate HRP-antibody 
conjugates at 1:10,000 dilution in blocking buffer. Membranes were then washed thoroughly before 
adding ECL Substrate (SuperSignal®, Pierce) and imaging using a Syngene® G:Box System.  
2.5. Biosensor construction and Bioreceptor Conjugation 
2.5.1. Electrode Preparation 
Customised DropSens® X2220AT gold electrodes were cleaned by ultra-sonication in 100 % ethanol 
for 10 min before rinsing in dH2O and drying in a stream of argon. The working electrodes were then 
coated in a matrix of polytyramine by electropolymerising from a monomer solution  (25 mM 
tyramine in 300 mM NaOH in MeOH) in accordance with previously established methods [28,29]. 
The solution was electrochemically polymerised onto the electrodes using cyclic voltammetry, with 
potential cycled between 0 V and 1.6 V (vs. Ag/AgCl) with a scan rate of 0.2 V.s-1 for two consecutive 
scans data shown in (Appendix C), before equilibrating for 15 min in PBS pH 7.4. 
2.5.2. Oriented conjugation of spacer modified nanobodies  
The polymer modified electrodes were incubated with 5 mM sulfosuccinimidyl 4-[N-
maleimidomethyl] cyclohexane-1-carboxylate (Sulfo-SMCC, Sigma) solution in 10 mM PBS-EDTA 
(10mM) pH 7.2 for one hour, as described in previous papers [30].Freshly reduced nanobodies (from 
2.2) were then added to the sulfo-SMCC modified electrode and incubated for 1 hr. These electrodes 
were incubated for 30 min in PBS pH 7.4 to remove any non-specifically bound receptor. The sensors 
were interrogated electrochemically prior to analyte detection to obtain a baseline sensor signal. 
2.5.3. Non-Oriented Conjugation of full antibodies and nanobodies  
For non-oriented bioreceptor studies, the bioreceptor (either Goat anti –rabbit IgG, ab 97047 
(Abcam) or the nanobody) was firstly biotinylated using biotin-XX-NHS (Merck Millipore) according 
to established protocols [31]. Biotinylated bioreceptors were then stored at -20  ? ?After electrode 
preparation (2.5.1), 3 mM biotin-E,^ŝŶW^ ? ? ?A?ǁ ?ǀD^K ?ǁĂƐŵĂĚĞĂŶĚ ? ?ʅůwas added to the 
working electrode for 60 min.  After copious washing, 1mM Neutravidin® was added to the 
ĞůĞĐƚƌŽĚĞĨŽƌ ? ?ŵŝŶďĞĨŽƌĞƌŝŶƐŝŶŐ ?ƚŚĞŶĨŝŶĂůůǇ ? ?ʅůŽĨƚŚĞďŝŽƚŝŶǇůĂƚĞĚƉƌŽƚĞŝŶǁĂƐĂĚĚĞĚĂŶĚ
incubated for 1 h.  The electrodes were once again incubated for 30 min in PBS after sensor 
assembly and a baseline signal obtained. 
2.6. Biosensor Interrogation 
After sensor assembly, electrochemical impedance spectroscopy (EIS) was used to monitor analyte 
recognition. Data was processed using NOVA software on a FRA-2 µAUTOLAB type III 
electrochemical workstation. The impedance analysis was performed over a frequency range from 
0.25 Hz to 25 kHz, using a modulation voltage of ±10 mV at an applied voltage of 0.0V with respect 
to the reference electrode. All impedance experiments were performed in an electrolyte solution of 
10 mM K3[Fe(CN)6]/  K4[Fe(CN)6] (1:1 ratio) in 1xPBS, pH 7.4. Fully fabricated immunosensors were 
ŝŶĐƵďĂƚĞĚǁŝƚŚ ? ?ʅůĂŶĂůǇƚĞ ?ƌĂďďŝƚĂŶƚŝƐŽǆ- 9, ab26414 (Abcam)) at a concentration ranging from 
666 fM to 666 nM for 30 min prior to sensor interrogation. The EIS response was read following 
copious rinsing of the analyte. 
2.7. Data Analysis 
Using Autolab NOVA Software, impedance data was modelled using a modified Randles’ circuit in 
which the pure capacitor was replaced with a constant-phase element to simulate the non-ideal 
nature of capacitance at the biosensor surface[32] (see Figure 4(B) inset) . As the effects of Warburg 
impedance were not observed in the data, this component was also excluded from the model.  Using 
this analysis, the simulated fit was found to have a deviation of 2.89 %± 0.096 (n=64) from the 
measured data. 
This fit generated values for Solution resistance (Rs), Charge Transfer resistance (Rct) and constant-
phase element (Q). For calibration of the biosensor Rct was used as it was the most sensitive to 
analyte binding and is the most widely used measure for impedimetric analysis of biosensors in the 
field [32–36]. To ensure chip-to-chip variability was minimised, values were normalised to the initial 
baseline of the RCT measured for the fully constructed sensor.  
3 Results  
3.1 Optimisation of synthesis and Dimer Reduction 
Nanobodies were successfully expressed in E.coli before being purified. In nanobodies with 
engineered cysteine terminal receptors, dimers natively formed. These dimers were reduced by 
incubation with 2-MEA (90mM, 37  ? ? ? ?ŵŝŶ ? ?ŽŶĨŝƌŵĂƚŝŽŶŽĨƚŚĞƉƵƌŝĨŝĐĂƚŝŽŶĂŶĚĚŝŵĞƌƌĞĚƵĐƚŝŽŶ
is illustrated in Figure 2. All lanes were run under non reducing conditions to ensure successful 
reduction of dimers could be observed. In all conditions the increasing molecular weight of the 
nanobodies can be observed, owing to the successful inclusion of the lengthening peptide spacer. 
The overall sample purity can also be clearly seen.   
3.2 Immunoprecipitation of IgG from rabbit sera  
Immunoprecipitation experiments illustrated that reduction had not denatured the nanobodies and 
that the use of the spacer had not interfered with the immune recognition of IgG by the nanobodies 
(Figure 3).  In this figure the Coomassie of different elutions from the experiment is shown with 
corresponding blots for the analyte as well as the nanobody receptors.  
Coomassie staining Figure 3(A) was done to assess the protein present in sera flow-through (s), 
glycine elution (gl) and DTT elution (dtt) of the immunoprecipitation experiments. Upon elution 
using glycine buffer bands can be observed at ~150 KDa corresponding to the molecular weight of 
IgG. When eluting with DTT bands are observed in the 12-15 KDa region, these correspond to the 
increasing molecular weight of the nanobody with their respective amino acid spacer.  
The identity of these bands was confirmed in western blot; firstly using a goat-anti-rabbit –HRP 
conjugated antibody (Dako cat# P0448) to identify the IgG band (Figure 3(B)). Secondly; an anti-
His6Tag –HRP conjugated antibody (Abcam cat# ab1187) was used to identify the nanobody, a band 
at 12-15KDa (Figure 3(C)). Across lanes, the signal is observed at increasing molecular weights 
corresponding to the 5, 10 and 15 amino acid peptide spacer modified nanobodies.  
3.3 Biosensor Construction and Interrogation 
Cyclic voltammetry (CV) verified the cleanliness and reproducibility of the gold surface before sensor 
construction (data not shown). Tyramine was then electrochemically polymerized on to the gold 
electrode in order to obtain a robust polymer with primary amino groups to permit functionalization 
of the sensor surface [29,37,38]. A characteristic cyclic voltammogram was seen across the two 
voltammetric cycles (Error! Reference source not found.), confirming the success of 
electropolymerisation. 
After the polymer was equilibrated in PBS for 15 min, biosensors were constructed as described 
before interrogation. Impedance measurements were taken from 25 KHz-250 mHz and Nyquist plots 
were constructed. Nyquist data as in (Figure 4) was used to assess the binding. The difference 
between specific (Figure 4(A)) and non-specific signal (Figure 4(B)) can be seen in the nyquist data.   
In order to allow cross comparison of the different nanobody biosensors with variable spacers 
against conventional antibody methods, Rct was analysed by modelling the equivalent circuit 
displayed in Figure 5, inset. The Rct was then used to calculate the average percent change compared 
with the initial sensor reading and construct a calibration. As sensors were interrogated suing 
specific rabbit IgG analyte and negative sheep IgG, a comparison of analyte specific signal obtained 
from different bioreceptor systems can be seen in Figure 5. 
It can be seen from this data that when using IgG as a receptor, the addition of analyte causes an 
increase in the resistance across the sensor interface. This follows conventional findings in the 
development of impedimetric immunosensors [3,35,39,40], as the passing of ions across the 
interface is slowed upon anlyte binding, corresponding to an increase in effective resistance.  
However, when using biotinylated nanobody as the receptor this is not the case. Instead a decrease 
in the resistnace is observed.  To confirm this, controls were performed with negative and positive 
controls using another sensor (for GFP constructed using anti-GFP nanobodies, (ab192863,Abcam) 
(Error! Reference source not found.). This confirmed that the decrease in resitance is both analyte 
dependent and observed consistently when using biotinylatyed nanobodies directly. This problem 
was successfully circumvented when using the oriented spacer. 
From data in Figure 5 we can observe that the use of an oriented peptide spacer of five amino acids 
was the optimum as it generated a large signal and was more sensitive, still generating appreciable 
signal at the lowest concentration of anlyte (666 fM). Biosensors constructed using ten amino acid 
spacers generated signal which was comparable to that obtained when using IgG as a receptor. 
When using a receptor with a fifteen amino acid spacer however there was negligible generation of 
specific signal.  
 
3.4 Optimisation of best candidate 
As the biosensor constructed using a bioreceptor with five amino acid peptide spacer had been 
identified as the best candidate, this was taken forward to be interrogated using a full panel of 
controls (Figure 6) in relevant sampling media to mimic sera. The sensor was interrogated with in 
PBS as an ideal system as well as a negative control using sheep IgG, data for these experiments was 
used to obtain calibration from Figure 5. In addition to this, human sera at both 100 and 10 % v/v in 
PBS was spiked with the same rabbit IgG to ensure that the biosensor is operational in a relevant 
sampling matrix.  
 
This demonstrated the successful detection of analyte in full sera and the overall specificity of the 
sensor in a complex media. Given that sera has a reference value of 60-80 mg.ml, an extremely high 
concertation when comparing to reference analyse range of the developed sensors , the sensor has 
proven successful.  When using undiluted sera an inferior calibration was observed. This may be due 
to the very high concentrations of non-specific proteins in the sample suppressing generation of 
signal by the analyte. In this dataset, the highest concentration of analyte resulted in a sudden 
decrease of signal. This may be due to transducer or receptor disintegration given the repeated 
barrage of high concentration protein samples and the high number of incubation-interrogation 
cycles. The sample spiked in 10% sera is the most successful showing large signal generation. This 
represents a practical sampling method, where a commercial or medical sample would be diluted 
before application to the sensor.   
4 Conclusion 
In this study, an impedimetric immunosensor to rabbit IgG was fabricated using bespoke nanobody 
constructs as bioreceptors and compared to traditional antibody based biosensors.  
When using conventional biosensor construction techniques with nanobodies, a negative calibration 
emerged, i.e. impedance fell on analyte binding which runs counter to most findings in this area. This 
trend was confirmed using a variety of controls and in the development of a similar sensor for green 
fluorescent protein (GFP). In both instances a change of ~40% in the Rct was observed.  
A peptide spacer was engineered to resolve this issue which also brought the advantage of orienting 
the receptor on the biosensor surface. The inclusion of the peptide spacer rectified the impedance 
drop and allowed the effect of spacing to be investigated. Optimisation of spacer length altered the 
signal and sensitivity of the sensor, leading to an improvement and a change of ~60% in the Rct to be 
observed. The optimal nanobody construct was observed with a peptide spacer of five amino acids. 
This sensor displayed reliable analyte specific signal down to pM analyte concentrations, 
demonstrating comparable sensitivity to established methods such as ELISA and superior 
performance to similar electrochemical biosensors  [41,42]. As typical samples have PM 
concentrations, this biosensor has an appropriate functional range and allows for sample dilution 
which is beneficial for practical deployment.  
In this study the spacer chosen had lengths of approximately 2, 4 and 6 nm which were compared to 
the solute layers present at the electrode interface. According to double layer theory and the Guoy-
Chapman model [32], the typical length of the Debye layer at the electrode interface of this 
electrolyte system has a thickness of  ~3 nm [32,43]. Using the five amino acid spacer therefore 
locates the receptor in the middle of the Debye layer. This may explain why the five amino acid 
spacer is optimal as longer spacers may place the receptor beyond the Debye layer, reducing the 
impedance signal generated upon analyte binding. The continued detection of analyte may be due 
to the spacer flexibility meaning that though the spacer length is greater than that of the Debye 
layer, it may flex and lead to some binding happening within the Debye layer. Along with the 
receptor being located optimally in the z-plane, the use of a five amino acid peptide spacer may also 
negate the effects of steric hindrance which could limit binding at the sensor interface. Though 
electrode surfaces are commonly depicted as planar surfaces, screen printed electrodes used are far 
from flat at the nanoscale.  This irregular texture may prevent the analyte from binding to the 
receptor when is confined at the surface. The effect of steric hindrance has been previously 
identified as an issue in biosensor fabrication[23,30,44].   
 Whilst this study is far from field deployment, improvements such as the reduction of chip-to-chip 
variability in the electrodes and automated sensor construction techniques could create more 
reliable sensors and enable effective point-of use testing comparable to ELISA assays or similar in a 
more user-friendly format. Using the recognised system of ‘technology readiness levels’ [45], this 
work is currently at level 4-5, relatively nascent compared to the ELISA, a routine technique used in 
industry (level 9).  This study has demonstrated for the fabrication of a sensitive and specific 
reagentless immunosensor using novel nanobody constructs. In addition to the advantages of using 
both unmodified and engineered nanobodies over polyclonal antibodies, this study presents insight 
relevant to the use of small binding proteins in electrochemical sensors, it is hoped that the lessons 
learnt in this study may inform the investigation of other NABP based sensors.  
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Figure 1: An Illustration of different bioreceptors used. Antibody based biosensors using full 
antibodies (a) and non-oriented (b) and oriented nanobody sensors with engineered peptide spacer 
(c) of 5, 10 and 15 amino acids, (1, 2 and 3 respectively). Figure is illustrative of the size difference 
between different receptors. 
 
Fig. 2 
 
 
Figure 2: non reducing SDS-PAGE of nanobody dimers and monomers. Coomassie staining of a gel run using MES buffer. 
The gel shows the nanobody under non-reducing and fully reducing conditions (DTT). 2-MEA lanes shows successful 
reduction of dimers which were then running SDS-Page under non reducing conditions [M=marker, B = basic nanobody, 
with no cysteine modification, 5, 10 and 15 are nanobodies with respective peptide spacers]. Arrows indicate dimers and 
monomers respectively.  
 
 
Fig. 3 
 
 
  
Figure 3: Coomassie stain (a) and immunoblot using anti rabbit IgG secondary (b) and anti his6-tag 
secondary (c). Across all panels diluted sera (s) are compared with fractions yielded from IP elutions, 
both glycine (gl) and DTT (dtt) respectively. In each  panel B, 5,10, 15 are the respective nanobody 
constructs with 5,10 and 15 amino acid spacer respectively alongside a non-specific control where 
Sulfolink® beads were blocked with buffer containing cysteine(-ve) 
 
Fig. 4 
  
Figure 4: Plot of impedance Nyquist data for a nanobody biosensor to detect rabbit IgG analyte. a) 
with Rabbit IgG (+ve) b)With Sheep IgG(-ve)    0 nM , 666 fM , 6.66 pM 666 pM 
, 666 nM . Illusrtrative data of one biosensor with nanobody bioreceptor with 5 amino 
acid spacer.  Inset (B) shows the equivalent cell used to Simulate data and derive calibration values. 
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 Figure 5: Comparison of analyte specific (total binding – non-specific binding) signal generated using 
different bioreceptor constructs ( P8D8;   P8D8-S5;   P8D8-S10;  
P8D8-S15;   IgG.) (n=5±StdEr).  Inset shows the equivalent cell used to simulate nyquist data 
and derive calibration values. 
 
 
Fig. 6 
 
Figure 6:  Performance of a biosensor for rabbit IgG constructed using five amino acid spacer (
rabbit IgG in 100% human sera;  rabbit IgG in PBS; rabbit IgG in 10% human 
sera: PBS(v:v); sheep IgG in PBS (-ve). (n=8±StdEr). 
